NJA-730
Undisclosed Immunological Indication
Phase 1Active
Key Facts
About NapaJen Pharma
NapaJen Pharma is a private, preclinical-stage biotech founded in 2015, headquartered in Seattle, USA, with a subsidiary in Japan. The company has developed a first-in-class drug delivery system (DDS) that selectively targets nucleic acid drugs to immune cells expressing the Dectin-1 receptor, such as macrophages and dendritic cells. Its platform enables both immunosuppressive and immunostimulatory therapies, with a lead candidate, NJA-730, having completed a Phase 1 trial. NapaJen operates a hybrid business model, pursuing both internal drug development and external partnerships to leverage its delivery platform.
View full company profile